The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients.
Tiziana Pressiani
No relevant relationships to disclose
Corrado Boni
No relevant relationships to disclose
Lorenza Rimassa
No relevant relationships to disclose
Roberto Labianca
No relevant relationships to disclose
Stefano Fagiuoli
No relevant relationships to disclose
Andrea Ardizzoni
No relevant relationships to disclose
Paolo Foa
No relevant relationships to disclose
Enrico Cortesi
No relevant relationships to disclose
Laura Giordano
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose